fluorouracil has been researched along with Pterygium in 26 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Pterygium: An abnormal triangular fold of membrane in the interpalpebral fissure, extending from the conjunctiva to the cornea, being immovably united to the cornea at its apex, firmly attached to the sclera throughout its middle portion, and merged with the conjunctiva at its base. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective study, 76 patients with primary pterygium (76 eyes) were categorized into two groups: the control group with 31 patients who did not receive cyclosporine treatment, and the cyclosporine group with 45 patients who received topical cyclosporine A (0." | 9.30 | Topical cyclosporine A 0.05% before and after surgery to prevent pterygium recurrence. ( Meneghim, RLFS; Natsuaki, KL; Oliveira, AC; Padovani, CR; Satto, LH; Schellini, SA; Viveiros, MMH, 2019) |
| "To compare 5-fluorouracil with conjunctival autograft with bevacizumab (avastin) used along with autograft in the surgical treatment of pterygium." | 9.22 | 5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium. ( Bekibele, CO; Ogundipe, A; Olaniyan, S; Sarimiye, TF, 2016) |
| "To compare the efficacy of 5-fluorouracil (5-FU) with mitomycin C (MMC) in preventing pterygium recurrence when used as an adjuvant following pterygium excision with conjunctival autograft." | 9.16 | 5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence. ( Ashaye, A; Baiyeroju, A; Bekibele, CO; Fasina, O; Ibrahim, AO; Ogun, O; Olusanya, B, 2012) |
| "To study the efficacy of subconjunctival 5-fluorouracil (5-FU) and triamcinolone injection in halting the progression of impending recurrent pterygium." | 9.12 | Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. ( Leelapatranura, K; Phonjan, T; Prabhasawat, P; Tesavibul, N, 2006) |
| "To investigate the efficacy of postoperative 5-fluorouracil (5-FU) in halting recurrence of pterygium." | 9.09 | Halting pterygium recurrence by postoperative 5-fluorouracil. ( Ophir, A; Pikkel, J; Porges, Y, 2001) |
| "To investigate the ocular surface changes occurring in eyes with recurrent pterygium post-operatively treated with 5-fluorouracil intralesional injections." | 7.91 | Ocular surface changes in recurrent pterygium cases post-operatively treated with 5-fluorouracil subconjunctival injections. ( Boto de Los Bueis, A; García Tirado, A; Rivas Jara, L, 2019) |
| "To compare the mean change in corneal astigmatism and clinical appearance after intralesional injection of 5-Fluorouracil in primary and recurrent pterygia." | 7.83 | Comparison of primary versus recurrent pterygium after intralesional 5-Fluorouracil. ( Basit, I; Khan, MS; Malik, S, 2016) |
| "To compare the effectiveness of intraoperative 5 fluorouracil (5-FU) and mitomycin C (MMC) application in preventing recurrence following primary pterygium excision." | 7.83 | Intraoperative application of 5-fluorouracil and mitomycin C aschemoadjuvants in primary pterygium surgery. ( Altay, Y; Balta, Ö, 2016) |
| "To evaluate the VEGF expression in macrophages, fibroblasts, and endothelial cells from pterygium before and after 5-fluorouracil (5-FU) exposure." | 7.81 | Expression of vascular endothelial growth factor (VEGF) in macrophages, fibroblasts, and endothelial cells in pterygium treated with 5-Fluorouracil. ( de Oliveira, DE; Hoyama, E; Padovani, CR; Schellini, SA; Selva, D; Shiratori, C; Viveiros, MM, 2015) |
| "To investigate the safety and efficacy of intraoperative application of 5-fluorouracil as an adjuvant in primary pterygium surgery and to evaluate the effect of postoperative subconjunctival 5-fluorouracil injections on the recurrent pterygium." | 7.72 | 5-Fluorouracil as chemoadjuvant for primary pterygium surgery: preliminary report. ( Akarsu, C; Ergin, A; Taner, P, 2003) |
| "The aim of this study was to compare 5-fluorouracil (5-FU) with beta-irradiation in the prevention of pterygium recurrence." | 7.72 | 5-fluorouracil vs. beta-irradiation in the prevention of pterygium recurrence. ( Ajayi, BG; Baiyeroju, AM; Bekibele, CO, 2004) |
| "Pterygium is an ultraviolet-related disease characterized by an aberrant, wing-shaped and active wound-healing process." | 6.82 | 5-Fluorouracil in primary, impending recurrent and recurrent pterygium: Systematic review of the efficacy and safety of a surgical adjuvant and intralesional antimetabolite. ( Coroneo, MT; Francis, IC; Lee, BWH; Sidhu, AS, 2022) |
| "A retrospective review of patients treated for pterygium recurrence was carried out." | 5.39 | Intra-lesional 5 fluorouracil for the management of recurrent pterygium. ( Dua, HS; Elalfy, MS; Faraj, LA; Fares, U; Maharajan, S; Miri, A; Otri, AM; Rahman, I; Said, DG; Yeung, A, 2013) |
| "In this prospective study, 76 patients with primary pterygium (76 eyes) were categorized into two groups: the control group with 31 patients who did not receive cyclosporine treatment, and the cyclosporine group with 45 patients who received topical cyclosporine A (0." | 5.30 | Topical cyclosporine A 0.05% before and after surgery to prevent pterygium recurrence. ( Meneghim, RLFS; Natsuaki, KL; Oliveira, AC; Padovani, CR; Satto, LH; Schellini, SA; Viveiros, MMH, 2019) |
| "To compare 5-fluorouracil with conjunctival autograft with bevacizumab (avastin) used along with autograft in the surgical treatment of pterygium." | 5.22 | 5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium. ( Bekibele, CO; Ogundipe, A; Olaniyan, S; Sarimiye, TF, 2016) |
| "To identify the determinants of recurrence following primary pterygium excision combined with conjunctival autograft (CAG) and intraoperative use of Mitomycin C (MMC) or 5-Fluorouracil (5-FU)." | 5.19 | Risk factors for pterygium recurrence after surgical excision with combined conjunctival autograft (CAG) and intraoperative antimetabolite use. ( Ashaye, AO; Baiyeroju, AM; Bekibele, CO; Fasina, O; Ibrahim, AO; Ogun, OA; Ogundipe, AO; Olusanya, BA, 2014) |
| "To compare 5 fluorouracil (5-FU) to conjunctival autograft in the treatment of large, fleshy pterygium." | 5.13 | Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft. ( Ashaye, AO; Baiyeroju, AM; Bekibele, CO; Oluleye, TS; Olusanya, BA, 2008) |
| "To study the efficacy of subconjunctival 5-fluorouracil (5-FU) and triamcinolone injection in halting the progression of impending recurrent pterygium." | 5.12 | Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. ( Leelapatranura, K; Phonjan, T; Prabhasawat, P; Tesavibul, N, 2006) |
| "To investigate the efficacy of postoperative 5-fluorouracil (5-FU) in halting recurrence of pterygium." | 5.09 | Halting pterygium recurrence by postoperative 5-fluorouracil. ( Ophir, A; Pikkel, J; Porges, Y, 2001) |
| "To investigate the ocular surface changes occurring in eyes with recurrent pterygium post-operatively treated with 5-fluorouracil intralesional injections." | 3.91 | Ocular surface changes in recurrent pterygium cases post-operatively treated with 5-fluorouracil subconjunctival injections. ( Boto de Los Bueis, A; García Tirado, A; Rivas Jara, L, 2019) |
| "The injection of 5 fluorouracil and Avastin act synergistically to arrest progression and induce atrophy in primary pterygium." | 3.91 | Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin). ( Britton, J; Dua, HS; Ghoz, N; Hogan, E; Mohammed, I; Ross, AR; Said, DG, 2019) |
| "To compare the mean change in corneal astigmatism and clinical appearance after intralesional injection of 5-Fluorouracil in primary and recurrent pterygia." | 3.83 | Comparison of primary versus recurrent pterygium after intralesional 5-Fluorouracil. ( Basit, I; Khan, MS; Malik, S, 2016) |
| "The literature reveals that pterygium surgery focuses on adjunctive therapy such as mitomycin C and 5-fluorouracil, and beta irradiation with bare sclera technique to decrease recurrence." | 3.73 | Conjunctival flaps for pterygium surgery. ( Anduze, AL, 2006) |
| "To investigate the safety and efficacy of intraoperative application of 5-fluorouracil as an adjuvant in primary pterygium surgery and to evaluate the effect of postoperative subconjunctival 5-fluorouracil injections on the recurrent pterygium." | 3.72 | 5-Fluorouracil as chemoadjuvant for primary pterygium surgery: preliminary report. ( Akarsu, C; Ergin, A; Taner, P, 2003) |
| "The aim of this study was to compare 5-fluorouracil (5-FU) with beta-irradiation in the prevention of pterygium recurrence." | 3.72 | 5-fluorouracil vs. beta-irradiation in the prevention of pterygium recurrence. ( Ajayi, BG; Baiyeroju, AM; Bekibele, CO, 2004) |
| "Pterygium is an ultraviolet-related disease characterized by an aberrant, wing-shaped and active wound-healing process." | 2.82 | 5-Fluorouracil in primary, impending recurrent and recurrent pterygium: Systematic review of the efficacy and safety of a surgical adjuvant and intralesional antimetabolite. ( Coroneo, MT; Francis, IC; Lee, BWH; Sidhu, AS, 2022) |
| "Pterygium is a frequent ocular disease, where the major challenge is the high level of recurrence after its surgical removal." | 2.58 | Comparison among adjuvant treatments for primary pterygium: a network meta-analysis. ( Arruda, GV; Fonseca, EC; Rocha, EM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 15 (57.69) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, BWH | 1 |
| Sidhu, AS | 1 |
| Francis, IC | 1 |
| Coroneo, MT | 1 |
| Fonseca, EC | 1 |
| Rocha, EM | 1 |
| Arruda, GV | 1 |
| García Tirado, A | 1 |
| Boto de Los Bueis, A | 1 |
| Rivas Jara, L | 1 |
| Ghoz, N | 1 |
| Britton, J | 1 |
| Ross, AR | 1 |
| Mohammed, I | 1 |
| Hogan, E | 1 |
| Said, DG | 2 |
| Dua, HS | 3 |
| Meneghim, RLFS | 1 |
| Satto, LH | 1 |
| Natsuaki, KL | 1 |
| Oliveira, AC | 1 |
| Padovani, CR | 2 |
| Viveiros, MMH | 1 |
| Schellini, SA | 2 |
| Faraj, LA | 1 |
| Elalfy, MS | 1 |
| Yeung, A | 1 |
| Miri, A | 1 |
| Fares, U | 1 |
| Otri, AM | 1 |
| Rahman, I | 1 |
| Maharajan, S | 1 |
| Hoyama, E | 1 |
| Viveiros, MM | 1 |
| Shiratori, C | 1 |
| de Oliveira, DE | 1 |
| Selva, D | 2 |
| Olusanya, BA | 2 |
| Ogun, OA | 1 |
| Bekibele, CO | 5 |
| Ashaye, AO | 2 |
| Baiyeroju, AM | 3 |
| Fasina, O | 2 |
| Ogundipe, AO | 1 |
| Ibrahim, AO | 2 |
| Sarimiye, TF | 1 |
| Ogundipe, A | 1 |
| Olaniyan, S | 1 |
| Malik, S | 1 |
| Khan, MS | 1 |
| Basit, I | 1 |
| Altay, Y | 1 |
| Balta, Ö | 1 |
| Sekundo, W | 1 |
| Droutsas, K | 1 |
| Cursiefen, C | 1 |
| Shousha, MA | 1 |
| Karp, CL | 1 |
| Perez, VL | 1 |
| Hoffmann, R | 1 |
| Ventura, R | 1 |
| Chang, V | 1 |
| Dubovy, SR | 1 |
| Wang, J | 1 |
| Ashaye, A | 1 |
| Olusanya, B | 1 |
| Baiyeroju, A | 1 |
| Ogun, O | 1 |
| Simon, S | 1 |
| Temlett, J | 1 |
| Chehade, M | 1 |
| Salustiano Correa E Silva, R | 1 |
| de Pereira Avila, M | 1 |
| Rassi, AR | 1 |
| Ximenes, L | 1 |
| da Silva, DS | 1 |
| de Paula, AC | 1 |
| Akarsu, C | 1 |
| Taner, P | 1 |
| Ergin, A | 1 |
| Ajayi, BG | 1 |
| Prabhasawat, P | 1 |
| Tesavibul, N | 1 |
| Leelapatranura, K | 1 |
| Phonjan, T | 1 |
| Oluleye, TS | 1 |
| Pherwani, A | 1 |
| Vakil, V | 1 |
| Eatamadi, H | 1 |
| Singh, R | 1 |
| Ben Simon, GJ | 1 |
| Ophir, A | 2 |
| Anduze, AL | 1 |
| Maldonado, MJ | 1 |
| Cano-Parra, J | 1 |
| Navea-Tejerina, A | 1 |
| Cisneros, AL | 1 |
| Vila, E | 1 |
| Menezo, JL | 1 |
| Pikkel, J | 1 |
| Porges, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Management of Recurrent Pterygium to Prevent Visual Impairment[NCT02530801] | Phase 4 | 25 participants (Anticipated) | Interventional | 2017-01-31 | Active, not recruiting | ||
| A Randomized Clinical Trial: Comparison of the Efficacy of Topical 0.2% Loteprednol Etabonate and Topical 0.1% Dexamethasone in Impending Recurrent Pterygium[NCT04075227] | Phase 4 | 108 participants (Actual) | Interventional | 2015-10-16 | Completed | ||
| Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study[NCT02342392] | Phase 2/Phase 3 | 36 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluorouracil and Pterygium
| Article | Year |
|---|---|
5-Fluorouracil in primary, impending recurrent and recurrent pterygium: Systematic review of the efficacy and safety of a surgical adjuvant and intralesional antimetabolite.
Topics: Antimetabolites; Conjunctiva; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Inj | 2022 |
Comparison among adjuvant treatments for primary pterygium: a network meta-analysis.
Topics: Adjuvants, Immunologic; Alkylating Agents; Chemotherapy, Adjuvant; Conjunctiva; Cyclosporine; Fluoro | 2018 |
[Operative techniques for surgical treatment of primary and recurrent pterygia].
Topics: Antimetabolites, Antineoplastic; Astigmatism; Biological Dressings; Combined Modality Therapy; Conju | 2010 |
8 trials available for fluorouracil and Pterygium
| Article | Year |
|---|---|
Topical cyclosporine A 0.05% before and after surgery to prevent pterygium recurrence.
Topics: Adult; Combined Modality Therapy; Conjunctiva; Corneal Diseases; Cyclosporine; Female; Fluorouracil; | 2019 |
Risk factors for pterygium recurrence after surgical excision with combined conjunctival autograft (CAG) and intraoperative antimetabolite use.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites; Combined Modality Therapy; | 2014 |
5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites; Autografts; Bevacizumab; C | 2016 |
5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Conjunctiva; Female; Fluoro | 2012 |
Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Conjunctiva; Disease Progression; Female; Fluorouracil | 2006 |
Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Conjunctiva; Disease Progression; Female; Fluorouracil | 2006 |
Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Conjunctiva; Disease Progression; Female; Fluorouracil | 2006 |
Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Conjunctiva; Disease Progression; Female; Fluorouracil | 2006 |
Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft.
Topics: Adult; Antimetabolites; Conjunctiva; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective St | 2008 |
Inefficacy of low-dose intraoperative fluorouracil in the treatment of primary pterygium.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Double-Blind Method; Female; Fluorouracil; | 1995 |
Halting pterygium recurrence by postoperative 5-fluorouracil.
Topics: Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Immunosuppressive Agents; Injections, In | 2001 |
15 other studies available for fluorouracil and Pterygium
| Article | Year |
|---|---|
Ocular surface changes in recurrent pterygium cases post-operatively treated with 5-fluorouracil subconjunctival injections.
Topics: Adult; Antimetabolites; Conjunctiva; Cornea; Epithelial Cells; Female; Fluorouracil; Follow-Up Studi | 2019 |
Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites; Bevacizumab; Biomarkers; Collagen Type I; Dru | 2019 |
Intra-lesional 5 fluorouracil for the management of recurrent pterygium.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Immunosuppressive Agents; Injections, Intralesional; Male | 2013 |
Expression of vascular endothelial growth factor (VEGF) in macrophages, fibroblasts, and endothelial cells in pterygium treated with 5-Fluorouracil.
Topics: Adult; Aged; Antimetabolites; Endothelial Cells; Female; Fibroblasts; Fluorouracil; Humans; Immunohi | 2015 |
Comparison of primary versus recurrent pterygium after intralesional 5-Fluorouracil.
Topics: Adult; Astigmatism; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intrales | 2016 |
Intraoperative application of 5-fluorouracil and mitomycin C aschemoadjuvants in primary pterygium surgery.
Topics: Fluorouracil; Follow-Up Studies; Humans; Intraoperative Care; Mitomycin; Prospective Studies; Pteryg | 2016 |
Diagnosis and management of conjunctival and corneal intraepithelial neoplasia using ultra high-resolution optical coherence tomography.
Topics: Administration, Topical; Aged; Aged, 80 and over; Biopsy; Carcinoma in Situ; Conjunctival Neoplasms; | 2011 |
Medial rectus Botox injection with pterygium excision and autograft as a novel technique for management of recurrent pterygium.
Topics: Aged; Antimetabolites; Botulinum Toxins, Type A; Cicatrix; Combined Modality Therapy; Conjunctiva; F | 2012 |
Intra-operative use of 5-Fluorouracil in pterygium surgery: a comparative study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Female; Fluorouracil; Humans; Intraoperative Care; | 2013 |
5-Fluorouracil as chemoadjuvant for primary pterygium surgery: preliminary report.
Topics: Adult; Conjunctiva; Female; Fluorouracil; Humans; Injections; Intraoperative Care; Male; Middle Aged | 2003 |
5-fluorouracil vs. beta-irradiation in the prevention of pterygium recurrence.
Topics: Antimetabolites; Beta Particles; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Midd | 2004 |
Postoperative subconjunctival 5-fluorouracil in the management of recurring pterygium.
Topics: Adult; Antimetabolites; Female; Fluorouracil; Humans; Pterygium; Secondary Prevention | 2007 |
Impending recurrent pterygium.
Topics: Antimetabolites, Antineoplastic; Conjunctiva; Fluorouracil; Glucocorticoids; Humans; Injections, Int | 2007 |
Impending recurrent pterygium.
Topics: Antimetabolites, Antineoplastic; Conjunctiva; Fluorouracil; Glucocorticoids; Humans; Injections; Inj | 2007 |
Conjunctival flaps for pterygium surgery.
Topics: Chemotherapy, Adjuvant; Conjunctiva; Fluorouracil; Humans; Mitomycin; Ophthalmologic Surgical Proced | 2006 |